EUCTR2009-014834-22-ITActive, not recruitingNot Applicable
A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, noninfectious,intermediate, posterior or panuveitis requiring immunosuppression (INSURE Study). - INSURE
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- OVARTIS FARMA
- Enrollment
- 208
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Patients eligible for inclusion in this study have to fulfill all of the following criteria: 1.Male and female subjects =18 years of age. Where relevant, parents will also sign the informed consent according to local laws and regulations. 2.Patients with diagnosis of chronic non-infectious intermediate uveitis, posterior uveitis or panuveitis in at least one eye 3.Evidence of active intermediate, posterior or panuveitis (grade = 2+ vitreous haze with or without the presence of anterior chamber cells) at screening and baseline in at least one eye 4.Requirement for any of the following immunosuppressive therapies for the treatment or prevention of uveitis -Prednisone or equivalent =10 mg daily at any time within the past 3 months - =1 periocular injection or =1 intravitreal corticosteroid injection (e.g. triamcinolone) in the study eye within the past 6 months (the last injection must not have been given 6 weeks prior to screening) -Treatment with either cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolic acid, methotrexate at any time within the past 3 months. (Patients treated with chlorambucil or cyclophosphamide within the past 5 years are ineligible for the study) -Patients not meeting the above specified criteria for immunosuppressive therapies are eligible for enrollment if they are intolerant to systemic immunosuppressive therapy as determined by the study investigator 5.Patient must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study assessment is performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Patients fulfilling any of the following criteria are not eligible for inclusion in this study: Ocular concomitant conditions/disease, specified in the protocol, page 26 Ocular treatments, specified in the protocol, page 26 Systemic conditions or treatments, specified in the protocol, page 26 Compliance/Administrative, specified in the protocol, page 27
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppression (INSURE Study) - INSUREdose ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppressionEUCTR2009-014834-22-HUovartis Pharma Services AG208
Active, not recruiting
Not Applicable
A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppression (INSURE Study) - INSUREon-infectious uveitis : intermediate, posterior or panuveitis requiring immunosuppressionMedDRA version: 12.1Level: LLTClassification code 10036370Term: Posterior uveitisMedDRA version: 12.1Level: LLTClassification code 10022557Term: Intermediate uveitisMedDRA version: 12.1Level: LLTClassification code 10033687Term: PanuveitisEUCTR2009-014834-22-FRovartis Pharma Services AG208
Active, not recruiting
Not Applicable
A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppression (INSURE Study) - INSUREdose ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppressionEUCTR2009-014834-22-GRovartis Pharma Services AG208
Active, not recruiting
Phase 1
A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppression (INSURE Study) - INSUREdose ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppressionEUCTR2009-014834-22-GBovartis Pharma Services AG
Active, not recruiting
Not Applicable
A 28-week multicenter, randomized, double-masked, placebo controlled, dose-ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppression (INSURE Study) - INSUREdose ranging phase III study to assess AIN457 versus placebo in inducing and maintaining uveitis suppression in adults with active, non-infectious, intermediate, posterior or panuveitis requiring immunosuppressionMedDRA version: 12.1Level: PTClassification code 10046851Term: UveitisEUCTR2009-014834-22-DEovartis Pharma Services AG208